Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Implantable cardioverter defibrillators in patients with cardiac amyloidosis.

Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA.

J Cardiovasc Electrophysiol. 2013 Jul;24(7):793-8. doi: 10.1111/jce.12123. Epub 2013 Mar 14.

PMID:
23489983
2.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505
3.

Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.

Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, Małecka B.

Kardiol Pol. 2012;70(11):1099-110.

4.

The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry.

Tsai VW, Cooper J, Garan H, Natale A, Ptaszek LM, Ellinor PT, Hickey K, Downey R, Zei P, Hsia H, Wang P, Hunt S, Haddad F, Al-Ahmad A.

Circ Heart Fail. 2009 May;2(3):197-201. doi: 10.1161/CIRCHEARTFAILURE.108.814525. Epub 2009 Apr 30.

5.

Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication.

Saba S, Atiga WL, Barrington W, Ganz LI, Kormos RL, MacGowan GA, Mathier MA, McNamara DM, Obioha-Ngwu O, Murali S.

J Heart Lung Transplant. 2003 Apr;22(4):411-8.

PMID:
12681418
6.

Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?

Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.

Circulation. 2006 Feb 14;113(6):776-82. Epub 2006 Feb 6.

7.

The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.

Olde Nordkamp LR, Wilde AA, Tijssen JG, Knops RE, van Dessel PF, de Groot JR.

Circ Arrhythm Electrophysiol. 2013 Feb;6(1):91-100. doi: 10.1161/CIRCEP.112.975268. Epub 2012 Dec 29.

8.

Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy.

Grimm W, Flores BT, Marchlinski FE.

Circulation. 1993 Jun;87(6):1880-8.

PMID:
8504500
9.
10.
11.
12.

Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery disease.

Blumer J, Wolber T, Hellermann J, Holzmeister J, Binggeli C, Duru F, Brunckhorst C.

Int Heart J. 2009 May;50(3):313-21.

13.

Sudden cardiac death and implantable cardioverter-defibrillators.

Turakhia MP.

Am Fam Physician. 2010 Dec 1;82(11):1357-66. Review.

14.

Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P.

N Engl J Med. 2000 Feb 10;342(6):365-73.

15.

Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.

Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.

Rev Port Cardiol. 2005 Mar;24(3):407-15. English, Portuguese.

PMID:
15929624
16.

Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.

Chen TB, Cheng KA, Gao P, Cheng ZW, Fan JB, Jiang XC, Fang Q.

Chin Med J (Engl). 2010 Apr 5;123(7):848-51.

PMID:
20497676
17.

[14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].

Vester EG, Dees H, Dobran I, Hennersdorf M, Perings C, Heydthausen M, Winter J, Strauer BE.

Z Kardiol. 2000;89 Suppl 3:194-205. German.

PMID:
10810803
18.

[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].

Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.

Rev Esp Cardiol. 2006 Jun;59(6):537-44. Spanish.

19.

Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.

Kreuz J, Skowasch D, Horlbeck F, Atzinger C, Schrickel JW, Lorenzen H, Nickenig G, Schwab JO.

Am J Cardiol. 2013 May 1;111(9):1319-23. doi: 10.1016/j.amjcard.2013.01.277. Epub 2013 Feb 11.

PMID:
23411108
20.

Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.

Dichtl W, Wolber T, Paoli U, Brüllmann S, Stühlinger M, Berger T, Spuller K, Strasak A, Pachinger O, Haegeli LM, Duru F, Hintringer F.

Clin Cardiol. 2011 Jul;34(7):433-6. doi: 10.1002/clc.20910. Epub 2011 Jun 15.

Supplemental Content

Support Center